发布求助
文献互助 智能选刊 最新文献

The Lancet. Oncology最新文献

筛选
英文 中文
Pursuing excellence in cancer care in Pakistan. 在巴基斯坦追求卓越的癌症治疗。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00295-9
Muhammed Aasim Yusuf
{"title":"Pursuing excellence in cancer care in Pakistan.","authors":"Muhammed Aasim Yusuf","doi":"10.1016/S1470-2045(22)00295-9","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00295-9","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"1365-1366"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40663518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Oncol 2022; 23: 1240-43. Lancet Oncol 2022更正;23日:1240 - 43。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00607-6
{"title":"Correction to Lancet Oncol 2022; 23: 1240-43.","authors":"","doi":"10.1016/S1470-2045(22)00607-6","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00607-6","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e492"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40664437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continuing enzalutamide with docetaxel in castration-resistant prostate cancer. 恩杂鲁胺联合多西他赛治疗去势抵抗性前列腺癌。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 Epub Date: 2022-10-18 DOI: 10.1016/S1470-2045(22)00614-3
Masaki Shiota
{"title":"Continuing enzalutamide with docetaxel in castration-resistant prostate cancer.","authors":"Masaki Shiota","doi":"10.1016/S1470-2045(22)00614-3","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00614-3","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"1345-1347"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40575343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma. 需要澄清派姆单抗作为透明细胞肾细胞癌的辅助治疗。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00601-5
Vivek Tarigopula, Prasant Nayak, Swarnendu Mandal, Manoj Kumar Das, Sambit Tripathy
{"title":"Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma.","authors":"Vivek Tarigopula, Prasant Nayak, Swarnendu Mandal, Manoj Kumar Das, Sambit Tripathy","doi":"10.1016/S1470-2045(22)00601-5","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00601-5","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e487"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40663525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma. 需要澄清派姆单抗作为透明细胞肾细胞癌的辅助治疗。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00602-7
Shuvadeep Ganguly, Ajay Gogia
{"title":"Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma.","authors":"Shuvadeep Ganguly, Ajay Gogia","doi":"10.1016/S1470-2045(22)00602-7","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00602-7","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e488"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40663526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rezvilutamide for metastatic hormone-sensitive prostate cancer - Authors' reply. 瑞兹维鲁胺治疗转移性激素敏感前列腺癌——作者的答复。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00630-1
Dingwei Ye, Weijie Gu, Junliang Li
{"title":"Rezvilutamide for metastatic hormone-sensitive prostate cancer - Authors' reply.","authors":"Dingwei Ye, Weijie Gu, Junliang Li","doi":"10.1016/S1470-2045(22)00630-1","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00630-1","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e491"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40664435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is the best way to treat patients with stage IIA or IIB seminoma? 治疗IIA期或IIB期精原细胞瘤的最佳方法是什么?
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 Epub Date: 2022-10-10 DOI: 10.1016/S1470-2045(22)00625-8
Patrizia Giannatempo, Nicola Nicolai
{"title":"What is the best way to treat patients with stage IIA or IIB seminoma?","authors":"Patrizia Giannatempo, Nicola Nicolai","doi":"10.1016/S1470-2045(22)00625-8","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00625-8","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"1349-1350"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hope for Africa's New Public Health Order to fight cancer. 非洲新公共卫生秩序抗击癌症的希望。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 Epub Date: 2022-10-14 DOI: 10.1016/S1470-2045(22)00611-8
Munyaradzi Makoni
{"title":"Hope for Africa's New Public Health Order to fight cancer.","authors":"Munyaradzi Makoni","doi":"10.1016/S1470-2045(22)00611-8","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00611-8","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"1362"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33513680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
First, do no harm: risk of secondary cancer after breast cancer treatment. 一、不危害:乳腺癌治疗后继发癌的风险。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 Epub Date: 2022-10-11 DOI: 10.1016/S1470-2045(22)00627-1
Hope S Rugo, Lisa Singer
{"title":"First, do no harm: risk of secondary cancer after breast cancer treatment.","authors":"Hope S Rugo, Lisa Singer","doi":"10.1016/S1470-2045(22)00627-1","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00627-1","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"1350-1352"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33511509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
WHO urges immediate action to tackle non-communicable diseases. 世卫组织敦促立即采取行动应对非传染性疾病。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 Epub Date: 2022-09-29 DOI: 10.1016/S1470-2045(22)00606-4
Manjulika Das
{"title":"WHO urges immediate action to tackle non-communicable diseases.","authors":"Manjulika Das","doi":"10.1016/S1470-2045(22)00606-4","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00606-4","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"1361"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信